• 

  May 2022 Molecules of the Month Runners Up

  Readers have been asking for more molecules, so this month, we’re starting a new feature that will highlight a few of the molecules we liked that didn’t make it into Molecules of the Month. There were six runners-up this month, including an orally bioavailable, brain penetrant inhibitor of PAAN/MIF, and a STING agonist discovered using…

• 

  Acceleron’s TGF-beta Ligand Trap, Trillium’s SIRP-alpha Fusion Proteins, and Eight Other Large Molecules Acquired in 2021

  Our team conducted a review of all of the biotech mergers and acquisitions of 2021 and distilled it down to the acquisitions of drug discovery-focused biotechs here. There were 10 acquisitions of companies with large molecule drug assets in 2021. Here is a more in-depth look into all of the lead large molecules acquired in 2021,…

• 

  Small Molecules Acquired in 2021 M&A: Deep Dive

  There were 16 acquisitions of companies with small molecule drug assets in 2021 and one merger. Here is a more in-depth look into all of the lead small molecules acquired in 2021, including a review of:  The lead molecules in each acquisition and their structural representations where disclosed The mechanism of action, stage, and indication…

• 

  FDA Novel Drug Approvals: May 2022

  There were two novel small molecules approved in May 2022: And one novel large molecule approval: This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins. See our overview of all 36 of the novel small molecule and large molecule…

• 

  2021 Drug Discovery Biotech IPO Trends

  We did a comprehensive review of all the initial public offerings for the biotech and pharmaceutical industry in 2021. This article is Part 1 in a review series about companies focused on drug discovery that IPO’d during this time. You can find recent years’ IPOs summarized here: 2020 Small Molecule IPOs 2020 Large Molecule IPOs…

• 

  The 2021 New Drug Approvals for Infectious Diseases: Deep Dive

  The FDA in 2021 approved four novel small molecule drugs for various infectious diseases, including human immunodeficiency virus type-1 (HIV-1), post-transplant cytomegalovirus (CMV), vulvovaginal candidiasis, and human African trypanosomiasis (HAT; sleeping sickness). This article and slide deck explores each in more detail, including but not limited to their: target rationale disease context original patents key…